AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen’s high-affinity anti-TIGIT antibody was licensed in 2018 to AstraZeneca for exclusive use in bi-specific and multi-specific antibody products, excluding PVRIG- and/or PVRL2- TIGIT-bispecific products
Navigating The Skies: Airbus’ Q1 Deliveries Reportedly Surge 12%
Airbus SE reports a 12% surge in Q1 aircraft deliveries, signaling recovery to 142 units, as per a media report. Despite falling short of initial expectations by approximately half a dozen planes, Airbus remains committed to meeting 2024 targets, aiming for 800 deliveries reports.
